AseBio Investor Day’s round table on fundraising in Europe gathered EIT Health Investor Network’s main stakeholders
Read moreConnecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...
Read moreThe Barcelona Science Park (PCB), a Spain's leading scientific, technological and business innovation hub in the life sciences field, aims to embark on a new phase of growth, offering more than 1,200 ...
Read moreA study published in the journal Science and coordinated by researchers of IDIBAPS and the UB describes a new immune defence mechanism unknown until now. It is a mechanism orchestrated by lipid drople...
Read moreEsta red pone en común diversos centros de investigación europeos para buscar sustancias biológicamente activas, como nuevos fármacos para tratar la Covid-19
Read moreMás colaboración público-privada, mayor inversión en I+D y crear un sólido ecosistema de investigación biomédica, tres ejes estratégicos necesarios para fortalecer el Sistema Nacional de Salud...
Read moreGENESIS Biomed is actively working in food innovation projects focused on improving human’s health
Read moreAsphalion has signed an agreement to be part of Barcelona Health Hub (BHH), the international digital health institution aiming to promote innovation in digital health and its transfer to the se...
Read moreBioga colabora con el Círculo de Empresarios de Galicia en la organización de la jornada “Biotecnología y Ciencias de la Vida”, que tendrá lugar el próximo miércoles 28 de octubre, de 9:00 a...
Read moreSparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...
Read moreThe Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes the last stage of the investment round with which this year it will ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read more